Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Can Editas, BeiGene Offerings Redeem US IPO Class Of 2015?

This article was originally published in Scrip

Executive Summary

US initial public offerings by biotechnology companies in 2015 dried up in November, but since Editas Medicine Inc. and BeiGene Ltd. had strong offerings to kick off February, does that mean that dozens of drug developers will be able to go public again in 2016?

Advertisement

Related Content

IPO Update: Three Biopharma Offerings In January Contrast With Last Year’s Slow Start
VC Roundup: Flagship’s New Fund Designed To Raise Its Stake In Startups
IPO Update: Values Slip As Four More Biopharma Firms Go Public In October
VC Roundup: October Brings Several New Venture Funds, Including Third Rock’s Fourth
Advertisement
UsernamePublicRestriction

Register